Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
| ▸ | CES2 | O00748 | 2/20 | 0.48 |
| ▸ | CES1 | P23141 | 2/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.43 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.43 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | SRC | P12931 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28910633 | 0.82 | ALDH1A1 (0.53) | ALDH1A1CYP3A4CES2CES1HSD17B10 | |
| SCHEMBL4595078 | 0.81 | HPGD (0.44) | ALDH1A1CYP3A4CES2CES1HSD17B10 | |
| SCHEMBL6702874 | 0.81 | CES2 (0.50) | ALDH1A1CYP3A4CES2CES1KMT2A | |
| SCHEMBL10583878 | 0.81 | ALDH1A1 (0.56) | ALDH1A1CYP3A4CES2CES1HSD17B10 | |
| SCHEMBL27654146 | 0.80 | CYP19A1 (0.41) | ALDH1A1CYP3A4CYP19A1LMNA | |
| SCHEMBL28068764 | 0.80 | KMT2A (0.46) | ALDH1A1CYP3A4CES2CES1KMT2A | |
| SCHEMBL27493692 | 0.80 | BRD4 (0.48) | ALDH1A1CYP3A4KMT2ACYP2D6LMNA | |
| SCHEMBL6176782 | 0.79 | CES2 (0.48) | ALDH1A1CYP3A4CES2CES1KMT2A | |
| SCHEMBL114464 | 0.79 | CYP2D6 (0.48) | CES2CES1KMT2ACYP2D6SRC | |
| SCHEMBL31650785 | 0.79 | CES2 (0.44) | ALDH1A1CYP3A4CES2CES1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117844320-A | Corrosion-resistant heat-insulating coating for integrally assembled self-supporting steel chimney and preparation method thereof | 希斯芮烟囱科技(连云港)有限公司 | 2024-04-09 | — | — | CN | claimed |
| CN-112010914-B | Glucosamine modified pentacyclic piperazine dione and preparation and application thereof | 首都医科大学 | 2023-06-27 | — | — | CN | claimed |
| US-20250376443-A1 | MASP-2 INHIBITORS AND METHODS OF USE | OMEROS CORPORATION (US) | 2025-12-11 | — | — | US | disclosed |
| US-20250368604-A1 | MASP-2 INHIBITORS AND METHODS OF USE | OMEROS CORPORATION (US) | 2025-12-04 | — | — | US | disclosed |
| CN-120349255-A | Synthesis method of (3-chlorophenyl ethyl) glycine benzyl ester | 吉尔多肽生物制药(大连市)有限公司 | 2025-07-22 | — | — | CN | disclosed |
| US-20250129020-A1 | MASP-2 INHIBITORS AND METHODS OF USE | OMEROS CORPORATION (US) | 2025-04-24 | — | — | US | disclosed |
| CN-119350433-A | MASP-2 inhibitors and methods of use | 奥默罗斯公司 | 2025-01-24 | — | — | CN | disclosed |
| US-12195427-B2 | MASP-2 inhibitors and methods of use | OMEROS CORPORATION (US) | 2025-01-14 | — | — | US | disclosed |
| CN-112867706-B | MASP-2 inhibitors and methods of use | 奥默罗斯公司 | 2024-11-15 | — | — | CN | disclosed |
| US-12116382-B2 | Functionalized N-acetylgalactosamine analogs | HONGENE BIOTECH CORPORATION (US) | 2024-10-15 | — | — | US | disclosed |
| US-20240252693-A1 | FOLATE RECEPTOR-TARGETED RADIOTHERAPEUTIC AGENTS AND THEIR USE | NOVARTIS PHARMACEUTICALS CORPORATION | 2024-08-01 | — | — | US | disclosed |
| EP-0267668-B1 | TRI- OR TETRA-2-HYDROXYBENZYL-1,2-DIAMINOALKANE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE FOR EXTRACTION OF GALLIUM | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1993-03-10 | — | — | EP | disclosed |
| US-5189033-A | Analgesics, antiiflammatory agents | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1993-02-23 | — | — | US | disclosed |
| US-5183940-A | For efficient extraction of gallium from basic solutions containing aluminates | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1993-02-02 | — | — | US | disclosed |
| WO-1992022564-A1 | IMMUNOSUPPRESSIVE AND TOLEROGENIC MODIFIED LEWISX AND LEWISA COMPOUNDS | ALBERTA RESEARCH COUNCIL (CA) | 1992-12-23 | — | — | WO | disclosed |
| EP-0480641-A1 | Tricyclic heterocycles | ZENECA LIMITED (GB) | 1992-04-15 | — | — | EP | disclosed |
| EP-0267668-A2 | Tri- or tetra-2-hydroxybenzyl-1,2-diaminoalkane derivatives, process for their preparation and their use for extraction of gallium | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1988-05-18 | — | — | EP | disclosed |
| US-4024273-A | Coronary vasodilator and anti-anginal compositions comprising substituted benzofurans and benzothiophenes and methods of producing coronary vasodilation and anti-anginal activity | SMITHKLINE CORPORATION (US) | 1977-05-17 | — | — | US | disclosed |
| US-3983245-A | CORONARY VASODILATORS | SMITHKLINE CORPORATION (US) | 1976-09-28 | — | — | US | disclosed |
| US-3947470-A | CORONARY VASODILATORS, TREATMENT OF ANGINA PECTORIS | SMITHKLINE CORPORATION (US) | 1976-03-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12116382-B2 | Functionalized N-acetylgalactosamine analogs | FUT6, CSGALNACT1, GALNT6 | ALDH1A1 1722/4885CYP3A4 4749/4885CES2 1344/4885 |
| US-20250368604-A1 | MASP-2 INHIBITORS AND METHODS OF USE | MASP2, METAP2, SPINT2 | ALDH1A1 4701/4885CYP3A4 4677/4885CES2 508/4885 |
| US-12195427-B2 | MASP-2 inhibitors and methods of use | MASP2, METAP2, SPINT2 | ALDH1A1 4701/4885CYP3A4 4677/4885CES2 508/4885 |
| US-20250376443-A1 | MASP-2 INHIBITORS AND METHODS OF USE | MASP2, METAP2, SPINT2 | ALDH1A1 4718/4885CYP3A4 4700/4885CES2 550/4885 |
| US-20240252693-A1 | FOLATE RECEPTOR-TARGETED RADIOTHERAPEUTIC AGENTS AND THEIR USE | FOLR1, FOLR2, FOLH1 | ALDH1A1 1704/4885CYP3A4 3972/4885CES2 1936/4885 |
| US-20250129020-A1 | MASP-2 INHIBITORS AND METHODS OF USE | MASP2, METAP2, SPINT2 | ALDH1A1 4701/4885CYP3A4 4677/4885CES2 508/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.